Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product.".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product.".